Cemsidomide vs Thalidomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
Cemsidomide
Developed by C4 Therapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07280013 (registry estimate)
No aligned efficacy figure on record for this race.
Thalidomide
Marketed by Bristol-Myers Squibb
NCT00083551 · Phase 3 · completed
The trial randomly assigned 323 participants to thalidomide and 345 to no thalidomide, but treatment was open-label rather than blinded. Its primary endpoint was the hard clinical outcome of six-year overall survival; although the reported percentages favored thalidomide, statistical significance cannot be determined from the posted registry data.
Next expected readout: August 2027 · NCT00572169 (registry estimate)
Reported efficacy
Overall Survival (6 Years): Overall Survival (6 Years): Thalidomide 65 percentage of participants | No Thalidomide 58 percentage of participants (unclear)
Result source: NCT00083551
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cemsidomide | Thalidomide |
|---|---|---|
| PFS, median | —Not reported | 46.7bNCT025413835 other results
|
| OS, median | —Not reported | 49.8bNCT005074162 other results
|
| ORR | —Not reported | 73%bNCT005074163 other results
|
| VGPR or better | —Not reported | 37%bNCT005074162 other results
|
| MRD negativity | —Not reported | —Not posted · NCT00083876 |
PFS, median
- Cemsidomide
- —Not reported
- Thalidomide
- 46.7bNCT02541383
5 other results
- 14.7 NCT00507416
- 15.4 NCT00507416
- 17.3 NCT00507416
- 22.5 vs 22.1 NCT01539083
- 52.8 NCT02541383
OS, median
- Cemsidomide
- —Not reported
- Thalidomide
- 49.8bNCT00507416
2 other results
- 51.5 NCT00507416
- 53.1 NCT00507416
ORR
- Cemsidomide
- —Not reported
- Thalidomide
- 73%bNCT00507416
3 other results
- 80% NCT00507416
- 70% NCT00507416
- 81.5% NCT00287872
VGPR or better
- Cemsidomide
- —Not reported
- Thalidomide
- 37%bNCT00507416
2 other results
- 51% NCT00507416
- 41% NCT00507416
MRD negativity
- Cemsidomide
- —Not reported
- Thalidomide
- —Not posted · NCT00083876
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Cemsidomide: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cemsidomide: 0 of 4 rows · Thalidomide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Thalidomide |
|---|---|
| Dropout rate | 0%a NCT00083551 · Phase 3 · combination show 20 more results—DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 20.7%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT00049673 · Phase 3 · registry result, not featured evidence 70.2%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 68.3%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 74.9%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 14.3% NCT00432458 · Phase 3 · registry result, not featured evidence · combination 89.3% NCT00097981 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT01632150 · Phase 2 · registry result, not featured evidence · combination — NCT00040937 · Phase 2 · registry result, not featured evidence · combination 0% NCT00081939 · Phase 2 · registry result, not featured evidence 0% NCT00083382 · Phase 2 · registry result, not featured evidence · combination 11.1% NCT00458705 · Phase 2 · registry result, not featured evidence · combination 0% NCT00287872 · Phase 2 · registry result, not featured evidence · combination 0%1000 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 0%800 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 0%600 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT00083551 · Phase 3 · combination show 20 more results—DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 5.5%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination — NCT00049673 · Phase 3 · registry result, not featured evidence 34.5%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 38.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 40.1%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination — NCT00432458 · Phase 3 · registry result, not featured evidence · combination 39.3% NCT00097981 · Phase 3 · registry result, not featured evidence · combination 17.5% NCT01632150 · Phase 2 · registry result, not featured evidence · combination — NCT00040937 · Phase 2 · registry result, not featured evidence · combination — NCT00081939 · Phase 2 · registry result, not featured evidence — NCT00083382 · Phase 2 · registry result, not featured evidence · combination 8.9% NCT00458705 · Phase 2 · registry result, not featured evidence · combination — NCT00287872 · Phase 2 · registry result, not featured evidence · combination —1000 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination —800 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination —600 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 100%a NCT00083551 · Phase 3 · combination show 20 more results49.3%DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination 18.8%DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 27.5%VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 34.6%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination 27.2%Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination 3% NCT00049673 · Phase 3 · registry result, not featured evidence 53.3%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 50.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 58.2%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 8.6% NCT00432458 · Phase 3 · registry result, not featured evidence · combination 50% NCT00097981 · Phase 3 · registry result, not featured evidence · combination — NCT01632150 · Phase 2 · registry result, not featured evidence · combination 1.3% NCT00040937 · Phase 2 · registry result, not featured evidence · combination 100% NCT00081939 · Phase 2 · registry result, not featured evidence 19.3% NCT00083382 · Phase 2 · registry result, not featured evidence · combination 48.9% NCT00458705 · Phase 2 · registry result, not featured evidence · combination 33.3% NCT00287872 · Phase 2 · registry result, not featured evidence · combination 0%1000 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 0%800 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 33.3%600 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a grade 1 bicarbonate decrease 60.1% (placebo 62.9%) grade 1 hypokalemia 54.2% (placebo 52.8%) grade 3 anemia (hgb) 49.8% (placebo 50.4%) NCT00083551 · Phase 3 · combination show 19 more resultsperipheral sensory neuropathy 60.6% constipation 50.6% asthenia 32.8% NCT02541383 · Phase 3 · registry result, not featured evidence · combination bronchitis 40.6% cough 17% nasopharyngitis 17% NCT02541383 · Phase 3 · registry result, not featured evidence bronchitis 36.5% cough 19.4% nasopharyngitis 17.5% NCT02541383 · Phase 3 · registry result, not featured evidence constipation 35.8% nausea 32.3% peripheral sensory neuropathy 24.4% NCT01539083 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 37.9% peripheral sensory neuropathy 36.9% neuropathy peripheral 29.1% NCT01539083 · Phase 3 · registry result, not featured evidence · combination neuropathy-sensory 89.1% (placebo 43.6%) fatigue 72.7% (placebo 58.3%) bone pain 72.1% (placebo 74.2%) NCT00049673 · Phase 3 · registry result, not featured evidence insomnia 5.5% weight decreased 2.4% blood sodium decreased 1.8% NCT00507416 · Phase 3 · registry result, not featured evidence · combination leukopenia 7.4% platelet count decreased 4.3% insomnia 3.7% NCT00507416 · Phase 3 · registry result, not featured evidence · combination hyperuricaemia 5.1% insomnia 3.8% cough 3.2% NCT00507416 · Phase 3 · registry result, not featured evidence · combination peripheral sensory neuropathy 80% fatigue 77.1% constipation 62.9% NCT00432458 · Phase 3 · registry result, not featured evidence · combination oedema peripheral 56.6% fatigue 54.7% constipation 45.3% NCT00097981 · Phase 3 · registry result, not featured evidence · combination sensory neuropathy 78.9% fatigue/malaise/lethargy 68.4% hyperglycemia 51.3% NCT00040937 · Phase 2 · registry result, not featured evidence · combination grade 1 bicarbonate decrease 72.3% grade 2 hypoalbuminemia 68.6% grade 1 alkaline phosphatase increase 59.7% NCT00081939 · Phase 2 · registry result, not featured evidence grade 1 hypomagnesemia 56.6% grade 2 fatigue 50.6% grade 1 hypocalcemia 47% NCT00083382 · Phase 2 · registry result, not featured evidence · combination thrombosis/thrombus/embolism 17.8% constipation 11.1% diarrhea 8.9% NCT00458705 · Phase 2 · registry result, not featured evidence · combination peripheral neuropathy 83.3% fatigue 73.3% constipation 63.3% NCT00287872 · Phase 2 · registry result, not featured evidence · combination 1000 mg somnolence 100% dysgeusia 66.7% febrile neutropenia 66.7% NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 800 mg diarrhea 100% nausea 100% somnolence 100% NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 600 mg somnolence 100% diarrhea 66.7% mucositis 66.7% NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Thalidomide
show 4 more results
show 4 more results
show 3 more results
show 3 more results
show 2 more results
show 2 more results
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemsidomide's landscape · Thalidomide's landscape